Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
E6 TCR gene therapy for HPV-16+ cancers
NCT02280811Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Oct 2014
- Primary completion
- Jun 2016
- Modality
- TCR-Engineered T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of E6 T cell receptor in vaginal cancer, Cervical Cancer (CC), anal cancer, penile cancer, oropharyngeal cancer, sponsored by National Cancer Institute. Started Oct 2014; status: completed.
02
Drugs
E6 T cell receptor
03
Conditions
vaginal cancerCervical Cancer (CC)anal cancerpenile canceroropharyngeal cancer
Beyond the preview
Go deeper on NCT02280811.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02280811.